Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms, Second Primary × Trastuzumab × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 520 Stomach Neoplasms 57 Neoplasm Metastasis 47 Neoplasms 35 HER2-positive Breast Cancer 29 Breast Neoplasms, Male 26 Colorectal Neoplasms 23 Brain Neoplasms 20 Esophageal Neoplasms 19 Carcinoma, Non-Small-Cell Lung 17 Inflammatory Breast Neoplasms 15 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 10 Endometrial Neoplasms 9 Colonic Neoplasms 9 Rectal Neoplasms 8 Ovarian Neoplasms 8 Adenocarcinoma Of Esophagus 7 Adenocarcinoma 7 Urinary Bladder Neoplasms 6 Sarcoma 6 Salivary Gland Neoplasms 6 Prostatic Neoplasms 6 Pathologic Complete Response 6 Lung Neoplasms 6 Gallbladder Neoplasms 6 Cardiotoxicity 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Breast Diseases 5

Interventions

Drug Therapy 3 Temozolomide 2 Radiotherapy 2 Leucovorin 2 Irinotecan 2 Fluorouracil 2 sacubitril and valsartan sodium hydrate drug combination 1 icotinib 1 beta Carotene 1 avelumab 1 alpha-Tocopherol 1 Varenicline 1 Tyrosine Kinase Inhibitors 1 Trastuzumab 1 Tobacco Use Cessation Devices 1 Therapeutics 1 Thalidomide 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Semen Analysis 1 Registries 1 Radiosurgery 1 Probiotics 1 Patient Reported Outcome Measures 1 Panitumumab 1 Nicotine Chewing Gum 1 Myofascial Release Therapy 1 Megestrol Acetate 1 Lenalidomide 1 Isotretinoin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03199300 2025-12-11

InvestiCAT

University Medical Center Groningen

Active not recruiting

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡